GSK (GSK) Stock Forecast & Price Target

GBX 1,486 -6.50 (-0.44%)

As of 03:38 AM Eastern

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 4 Analyst Ratings

Sell
1

Hold
2

Buy
1

Based on 4 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 1 has given a sell rating, 2 have given a hold rating, and 1 has given a buy rating for GSK.

Consensus Price Target

GBX 1,612.50

According to the 4 analysts' twelve-month price targets for GSK, the average price target is GBX 1,612.50. The highest price target for GSK is GBX 2,000, while the lowest price target for GSK is GBX 1,400. The average price target represents a forecasted upside of 8.51% from the current price of GBX 1,486.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

GSK Analyst Ratings Over Time

Type	Current Forecast 8/22/24 to 8/22/25	1 Month Ago 7/23/24 to 7/23/25	3 Months Ago 5/24/24 to 5/24/25	1 Year Ago 8/23/23 to 8/22/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	GBX 1,612.50	GBX 1,683.33	GBX 1,862.50	GBX 1,805.71
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies
Consensus Rating Score	2.00	2.79
Consensus Rating	Hold	Moderate Buy
News Sentiment Rating	Neutral News See Recent GSK News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
8/4/2025	JPMorgan Chase & Co. 2 of 5 stars	Lower Target	Underweight	GBX 1,460 ➝ GBX 1,400	+0.68%
7/31/2025	Deutsche Bank Aktiengesellschaft 2 of 5 stars	Reiterated Rating	Hold	GBX 1,450	+1.29%
7/30/2025	Shore Capital 1 of 5 stars	Reiterated Rating	Buy	GBX 2,000	+41.06%
7/18/2025	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold	GBX 1,600	+17.69%
7/5/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy	GBX 2,120 ➝ GBX 1,900	+24.79%
6/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	GBX 2,100	+38.25%
5/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	GBX 1,725	-1.96%
9/25/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		GBX 1,440 ➝ GBX 1,585	+3.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:00 AM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, August 20, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

The current stock price is around $19.58, which has recently crossed above its 200-day moving average, indicating potential upward momentum.
GSK plc has received a "buy" rating from Shore Capital, with a target price of GBX 2,000, suggesting significant upside potential from current levels.
The company reported a solid earnings per share (EPS) of GBX 75.30 for the last quarter, reflecting strong financial performance.
GSK plc has a relatively low beta of 0.31, indicating lower volatility compared to the market, which may appeal to risk-averse investors.
Analysts anticipate a positive growth trajectory, with expectations of an EPS of approximately 176 for the current fiscal year, indicating potential for future profitability.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

JPMorgan Chase & Co. has downgraded its price target for GSK plc from GBX 1,460 to GBX 1,400, indicating a cautious outlook on the stock.
The company has a high debt-to-equity ratio of 114.64, which may raise concerns about financial stability and the ability to manage debt effectively.
Despite recent positive performance, GSK plc has a consensus rating of "Hold," suggesting that many analysts are not fully confident in its growth prospects.
GSK plc's net margin of 8.02% may be considered low compared to industry standards, which could limit profitability and investor returns.
Insider trading activity, such as the purchase of only 9 shares by an insider, may indicate a lack of confidence in the stock's future performance among company executives.

GSK Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 1,612.50, with a high forecast of GBX 2,000 and a low forecast of GBX 1,400.
: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
: According to analysts, GSK's stock has a predicted upside of 8.51% based on their 12-month stock forecasts.
: GSK has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., and Shore Capital in the past 90 days.
: Analysts like GSK less than other "medical" companies. The consensus rating for GSK is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (LON:GSK) was last updated on 8/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target